Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.

Hdl Handle:
http://hdl.handle.net/10147/297470
Title:
Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.
Authors:
Ahern, T; Tobin, A-M; Corrigan, M; Hogan, A; Sweeney, C; Kirby, B; O'Shea, D
Affiliation:
Obesity Research Group, and Dermatology Research Group, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
Citation:
Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. 2012: J Eur Acad Dermatol Venereol
Publisher:
Journal of the European Academy of Dermatology and Venereology : JEADV
Journal:
Journal of the European Academy of Dermatology and Venereology : JEADV
Issue Date:
13-Jun-2012
URI:
http://hdl.handle.net/10147/297470
DOI:
10.1111/j.1468-3083.2012.04609.x
PubMed ID:
22691169
Abstract:
Background  Diabetes and obesity are more prevalent amongst psoriasis patients as is disturbance of the innate immune system. GLP-1 analogue therapy considerably improves weight and glycaemic control in people with type 2 diabetes and its receptor is present on innate immune cells. Objective  We aimed to determine the effect of liraglutide, a GLP-1 analogue, on psoriasis severity. Methods  Before and after 10 weeks of liraglutide therapy (1.2 mg subcutaneously daily) we determined the psoriasis area and severity index (PASI) and the dermatology life quality index (DLQI) in seven people with both psoriasis and diabetes (median age 48 years, median body mass index 48.2 kg/m(2) ). We also evaluated the immunomodulatory properties of liraglutide by measuring circulating lymphocyte subset numbers and monocyte cytokine production. Results  Liraglutide therapy decreased the median PASI from 4.8 to 3.0 (P = 0.03) and the median DLQI from 6.0 to 2.0 (P = 0.03). Weight and glycaemic control improved significantly. Circulating invariant natural killer T (iNKT) cells increased from 0.13% of T lymphocytes to 0.40% (P = 0.03). Liraglutide therapy also effected a non-significant 54% decrease in the proportion of circulating monocytes that produced tumour necrosis factor alpha (P = 0.07). Conclusion  GLP-1 analogue therapy improves psoriasis severity, increases circulating iNKT cell number and modulates monocyte cytokine secretion. These effects may result from improvements in weight and glycaemic control as well as from direct immune effects of GLP-1 receptor activation. Prospective controlled trials of GLP-1 therapies are warranted, across all weight groups, in psoriasis patients with and without type 2 diabetes.
Item Type:
Article
Language:
en
ISSN:
1468-3083

Full metadata record

DC FieldValue Language
dc.contributor.authorAhern, Ten_GB
dc.contributor.authorTobin, A-Men_GB
dc.contributor.authorCorrigan, Men_GB
dc.contributor.authorHogan, Aen_GB
dc.contributor.authorSweeney, Cen_GB
dc.contributor.authorKirby, Ben_GB
dc.contributor.authorO'Shea, Den_GB
dc.date.accessioned2013-08-07T08:46:11Z-
dc.date.available2013-08-07T08:46:11Z-
dc.date.issued2012-06-13-
dc.identifier.citationGlucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. 2012: J Eur Acad Dermatol Venereolen_GB
dc.identifier.issn1468-3083-
dc.identifier.pmid22691169-
dc.identifier.doi10.1111/j.1468-3083.2012.04609.x-
dc.identifier.urihttp://hdl.handle.net/10147/297470-
dc.description.abstractBackground  Diabetes and obesity are more prevalent amongst psoriasis patients as is disturbance of the innate immune system. GLP-1 analogue therapy considerably improves weight and glycaemic control in people with type 2 diabetes and its receptor is present on innate immune cells. Objective  We aimed to determine the effect of liraglutide, a GLP-1 analogue, on psoriasis severity. Methods  Before and after 10 weeks of liraglutide therapy (1.2 mg subcutaneously daily) we determined the psoriasis area and severity index (PASI) and the dermatology life quality index (DLQI) in seven people with both psoriasis and diabetes (median age 48 years, median body mass index 48.2 kg/m(2) ). We also evaluated the immunomodulatory properties of liraglutide by measuring circulating lymphocyte subset numbers and monocyte cytokine production. Results  Liraglutide therapy decreased the median PASI from 4.8 to 3.0 (P = 0.03) and the median DLQI from 6.0 to 2.0 (P = 0.03). Weight and glycaemic control improved significantly. Circulating invariant natural killer T (iNKT) cells increased from 0.13% of T lymphocytes to 0.40% (P = 0.03). Liraglutide therapy also effected a non-significant 54% decrease in the proportion of circulating monocytes that produced tumour necrosis factor alpha (P = 0.07). Conclusion  GLP-1 analogue therapy improves psoriasis severity, increases circulating iNKT cell number and modulates monocyte cytokine secretion. These effects may result from improvements in weight and glycaemic control as well as from direct immune effects of GLP-1 receptor activation. Prospective controlled trials of GLP-1 therapies are warranted, across all weight groups, in psoriasis patients with and without type 2 diabetes.en_GB
dc.languageENG-
dc.language.isoenen
dc.publisherJournal of the European Academy of Dermatology and Venereology : JEADVen_GB
dc.rightsArchived with thanks to Journal of the European Academy of Dermatology and Venereology : JEADVen_GB
dc.titleGlucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.en_GB
dc.typeArticleen
dc.contributor.departmentObesity Research Group, and Dermatology Research Group, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.en_GB
dc.identifier.journalJournal of the European Academy of Dermatology and Venereology : JEADVen_GB
dc.description.fundingOtheren
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.